DOP20: The impact of early life antibiotics on the occurrence of paediatric inflammatory bowel disease - a nationwide study from 1995 – 2018ECCO’23 CopenhagenYear: 2023
Authors: Jawad, A.(1);Jansson, S.(1,2);Malham, M.(1,2)*;Wewer, V.(1,2);
(1)Copenhagen University Hospital - Hvidovre, Department of Paediatric and Adolescence Medicine, Hvidovre, Denmark;(2)Copenhagen University Hospital - Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adult
DOP21: Disease activity patterns of paediatric Inflammatory Bowel Disease – A Danish nationwide cohort study 1996-2018ECCO’23 CopenhagenYear: 2023
Authors: Wewer, M.D.(1,2,3)*;Jansson, S.(3,4,5);Malham, M.(3,4,6);Burisch, J.(1,3);Wewer, V.(3,4,7);
(1)Hvidovre Hospital, Gastrounit- Medical Division, Hvidovre, Denmark;(2)University of Copenhagen, Medical Faculty, Copenhagen, Denmark;(3)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Hvidovre Hospital, The Department of Paediatrics and Adolescent Medicine, Hvidovre, Denmark;(5)University of Aarhus, Medical Faculty, Aarhus, Denmark;(6)University of Copenhagen, Section of Epidemiology- Department of Public Health, Copenhagen, Denmark;(7)University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark;
DOP22: Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A Population-Based Cohort StudyECCO’23 CopenhagenYear: 2023
Authors: Faye, A.(1)*;Allin, K.(2);Iversen, A.(3);Agrawal, M.(4);Faith, J.(5);Colombel, J.F.(5);Jess, T.(2);
(1)NYU Grossman School of Medicine, Medicine, New York City, United States;(2)PREDICT- Aalborg University, Medicine, Copenhagen, Denmark;(3)PREDICT, Medicine, Copenhagen, Denmark;(4)Icahn School of Medicine at Mount Sinai- PREDICT, Medicine, New York City, United States;(5)Icahn School of Medicine at Mount Sinai, Medicine, New York City, United States;
DOP23: Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST surveyECCO’23 CopenhagenYear: 2023
Authors: Roukas, C.(1)*;Miller , L.(2);Hamborg, T.(2);Gordeev, V.(1);Lindsay, J.(3);Norton, C.(4);Mihaylova, B.(1);
(1)Wolfson Institute of Population Health, Health Economics and Policy Research Unit, London, United Kingdom;(2)Wolfson Institute of Population Health, Pragmatic Clinical Trials Unit, London, United Kingdom;(3)Blizard Institute, Centre for Immunobiology, London, United Kingdom;(4)Faculty of Nursing, Midwifery and Palliative Care, London, United Kingdom;
DOP24: Early life exposures and risk for inflammatory bowel disease: a nested case-control study in Quebec, CanadaECCO’23 CopenhagenYear: 2023
Authors: Fantodji, C.(1)*;Rousseau, M.C.(1);Nicolau, B.(2);Madathil, S.(2);Benedetti, A.(3);Jantchou, P.(4);
(1)Institut national de la recherche scientifique INRS- Université du Québec, Epidemiology and Biostatistics Unit- Centre Armand-Frappier Santé Biotechnologie, Laval, Canada;(2)McGill University, Faculty of Dental Medicine and Oral Health Sciences, Montréal, Canada;(3)McGill University, Departments of Medicine and of Epidemiology- Biostatistics & Occupational Health, Montréal, Canada;(4)Sainte-Justine University Hospital Centre CHU Sainte-Justine, Department of Gastroenterology- Hepatology- and Nutrition, Montréal, Canada;
DOP25: Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United StatesECCO’23 CopenhagenYear: 2023
Authors: Brenner, E.(1)*;Zhang, X.(2);Long, M.(3);Dubinsky, M.(4);Kappelman, M.(2);
(1)University of North Carolina, Pediatrics, Chapel Hill, United States;(2)University of North Carolina at Chapel Hill, Pediatrics, Chapel Hill, United States;(3)University of North Carolina at Chapel Hill, Medicine, Chapel Hill, United States;(4)Mount Sinai, Pediatrics, New York, United States;
DOP26: Burden of perianal disease and perianal surgery in Crohn's disease over different therapeutic eras – a population-based study from western Hungary between 1977–2020, data from the Veszprem county cohortECCO’23 CopenhagenYear: 2023
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.A.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(5)*;
(1)Semmelweis University, Department of Medicine and Oncology, Budapest, Hungary;(2)Ferenc Csolnoky Hospital, Department of Gastroenterology, Veszprem, Hungary;(3)Hungarian Defence Forces Medical Centre, Department of Gastroenterology, Budapest, Hungary;(4)Grof Esterhazy Hospital, Department of Gastroenterology, Papa, Hungary;(5)Mcgill University Health Center, IBD Centre, Montréal, Canada;
DOP27: Disease activity patterns in the first 5 years after diagnosis in children with Crohn's disease: a population-based study.ECCO’23 CopenhagenYear: 2023
Authors: Distante, M.(1);Rotulo, S.(1)*;Ranalli, M.(1);Pedace, E.(1);Lionetti, P.(2);Arrigo, S.(3);Alvisi, P.(4);Miele, E.(5);Martinelli, M.(5);Zuin, G.(6);Bramuzzo, M.(7);Cananzi, M.(8);Aloi, M.(1);
(1)Umberto I Hospital- Sapienza University of Rome, Department of Maternal and Child Health- Pediatric Gastroenterology and Liver Unit, Rome, Italy;(2)Meyer Children's Hospital, Unit of Gastroenterology and Nutrition, Florence, Italy;(3)IRCCS- Istituto Giannina Gaslini, Gastroenterologia ed Endoscopia Pediatrica, Genoa, Italy;(4)Maggiore Hospital, Pediatric Gastroenterology Unit, Bologna, Italy;(5)University of Naples “Federico II”, Department of Translational Medical Science- Section of Pediatrics, Naples, Italy;(6)Fondazione MBBM- San Gerardo Hospital, Pediatric Department- University of Milano Bicocca, Monza, Italy;(7)IRCCS “Burlo Garofolo”, Institute for Maternal and Child Health, Trieste, Italy;(8)University Hospital of Padova, Unit of Gastroenterology- Digestive Endoscopy- Hepatology and Care of Children with Liver Transplantation, Padova, Italy;SIGENP IBD Working Group: C. Romano, M.T. Illiceto, S. Salvatore, V. Romagnoli, C. De Giacomo, D.Knafelz, G. Barera, M. Corpino, R. Cozzali, A. Ravelli, G. Castellucci, P. Diaferia, D. Dilillo, M. Baldi, E. Felici, C. Banzato, P.M. Pavanello
DOP28: Aconitate decarboxylase 1 (ACOD1) represents a crucial regulator of monocyte recruitment, survival and proinflammatory status in intestinal inflammationECCO’23 CopenhagenYear: 2023
Authors: Jones, G.R.(1)*;Hegarty, L.(1);T'Jonck, W.(1);Adams, C.(1);Drury, B.(1);Byrne, A.(2);Ho, G.T.(1);Bain, C.(1);
(1)The Queens Medical Research Institute, Centre for inflammation research, Edinburgh, United Kingdom;(2)Faculty of Medicine- National Heart & Lung Institute, Imperial College, London, United Kingdom;
DOP29: Single cell analysis of Crohn's disease fistula; comparison of different locationsECCO’23 CopenhagenYear: 2023
Authors: Beckerdrs., M.(1)*;Koelink, P.(1);Bemelman, W.(2);Buskens, C.(2);Wildenberg, M.(1);
(1)Tytgat Institute for Liver and Intestinal Research, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Surgery, Amsterdam, The Netherlands;
DOP30: Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-OmicsECCO’23 CopenhagenYear: 2023
Authors: Haberman Ziv, Y.(1)*;Braun, T.(1);Amir, A.(1);Levhar, N.(1);Toren, I.(1);Malik, A.(2);Neuman, S.(2);Hadar, R.(1);Efroni, G.(1);Ben-Horin, S.(2);
(1)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(2)Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;The Leona M. and Harry B. Helmsley Charitable Trust SOURCE consortium investigators
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Briola, A.(1);Havlik, J.(2);Mascellani, A.(2);Milling, S.(3);Ijaz, U.(4);Quince, C.(5);Svolos, V.(1);Russell, R.K.(6);Hansen, R.(7);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Czech University of Life Sciences Prague, Food Science, Prague, Czech Republic;(3)University of Glasgow, School of Immunology, Glasgow, United Kingdom;(4)University of Glasgow, School of Engineering, Glasgow, United Kingdom;(5)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(6)Royal Hospital for Sick Children and Young People, Paediatric Gastroenterology- Hepatology and Nutrition, Edinburgh, United Kingdom;(7)Royal Hospital for Children, Paediatric Gastroenterology- Hepatology & Nutrition, Glasgow, United Kingdom;
DOP32: Crohn's disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)ECCO’23 CopenhagenYear: 2023
Authors: Lin, S.(1);Wang, J.(2);Mukherjee, P.(3);Mao, R.(1);West, G.(3);Czarnecki, D.(3);Zhao, S.(3);Elias, M.(3);Nguyen, Q.T.(3);Chandra, J.(3);Le, T.H.N.(3);Chen, M.H.(1);Dejanovic, D.(3);Holubar, S.(4);Olman, M.(3);Southern, B.(3);Hu, S.(5);Gordon, I.O.(5);Atabai, K.(6);Fiocchi, C.(3);Rieder, F.(7)*;
(1)The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology and Hepatology, Guangzhou, China;(2)Xinxiang Medical University, Henan Key Laboratory of Immunology and Targeted Drug, Xinxiang, China;(3)Cleveland Clinic, Inflammation and Immunity, Cleveland, United States;(4)Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(5)Cleveland Clinic, Department of Pathology, Cleveland, United States;(6)University of California San Francisco, Cardiovascular Research Institute, San Francisco, United States;(7)Cleveland Clinic, Gastroenterology- Hepatology and Nutrition, Cleveland, United States;
DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Ke, B.J.(1);Abdurahiman, S.(1);Biscu, F.(1);Verstockt, S.(1);Verstockt, B.(2);de Hertogh, G.(3);Vermeire, S.(2);Matteoli, G.(1)*;
(1)KU Leuven, Translational Research Center for Gastrointestinal Disorders- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospitals Leuven, Department of Pathology, Leuven, Belgium;
DOP34: Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Li, Y.(1)*;Yu, Z.(1);Schenk, M.(1);Lagovsky, I.(2);Illig, D.(1);Walz, C.(3);Rohlfs, M.(1);Conca, R.(1);Muise, A.(4);Snapper, S.(5);Uhlig, H.(6);Garty, B.(7);Klein, C.(1);Kotlarz, D.(1);
(1)Dr. von Hauner Children's Hospital- Ludwig-Maximilians-Universität LMU, Department of Pediatrics, Munich, Germany;(2)Rabin Medical Center and Sackler School of Medicine, Felsenstein Medical Research Center, Tel Aviv, Israel;(3)Faculty of Medicine- LMU Munich, Institute of Pathology, Munich, Germany;(4)Hospital for Sick Children, SickKids Inflammatory Bowel Disease Center, Toronto, Canada;(5)Boston Children's Hospital, Division of Gastroenterology- Hepatology and Nutrition, Boston, United States;(6)University of Oxford, Translational Gastroenterology Unit and Department of Pediatrics- and Biomedical Research Centre, Oxford, United Kingdom;(7)Tel Aviv University, Sackler School of Medicine, Tel-Aviv, Israel;
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitisECCO’23 CopenhagenYear: 2023
Authors: Li, M.(1)*;Dong, Y.(1);Zhang, K.(1);Ma, J.(1);He, L.(1);Wei, J.(1);Jiang, J.(1);Zhao, Q.(1);Zhao, Q.(1);Cao, H.(1);
(1)Tianjin Medical University General Hospital, Department of Gastroenterology and Hepatology, Tianjin, China;
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signatureECCO’23 CopenhagenYear: 2023
Authors: Pisani, L.F.(1,2)*;Crespi, G.(3,4);Mellai, M.(4,5);Flavio, C.(6,7);Annunziata, M.L.(8);Manfredi, M.(4,9);Luca, P.(10,11);Porta, C.(3,4);
(1)University of Milano-Bicocca, Department of Biotechnology and Biosciences BtBs, Milan, Italy;(2)IRCCS Policlinico San Donato, Gastroenterology and Endoscopy Unit, San Donato Milanese, Italy;(3)University of Piemonte Orientale, Department of Pharmaceutical Sciences, Novara, Italy;(4)University of Piemonte Orientale, Center for Translational Research on Autoimmune and Allergic Diseases, Novara, Italy;(5)University of Piemonte Orientale, Department of Health Sciences, Novara, Italy;(6)University of MIlan, Department of Medical-Surgical Physiopathology and Transplantation, Milan, Italy;(7)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Gastroenterology end endoscopy unit, Milan, Italy;(8)IRCCS Policlinico San Donato, Gastreoenterology and Endoscopy Unit, San Donato Milanese, Italy;(9)University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy;(10)University of Milan, Department of Health Sciences, Milan, Italy;(11)ASST Santi Paolo e Carlo, Gastroenterology and Liver Unit, Milan, Italy;
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Danese, S.(1)*;Abreu, M.T.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Panaccione, R.(5);Afzali, A.(6);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Head Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(2)University of Miami Miller School of Medicine, Gastroenterology Division, Miami, United States;(3)Atlanta Gastroenterology Associates LLC, IBD Research, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Inflammatory Bowel Disease Clinic, IBD Research, Alberta, Canada;(6)University of Cincinnati College of Medicine, Gastroenterology, Cincinnati, United States;
DOP38: Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction TherapyECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Hisamatsu, T.(2);Bresso , F.(3);Thin, L.(4);Parra, R.(5);Ford, S.(6);Remple, V.(6);Lacerda, A.P.(6);Hecht, P.(6);Mallick, M.(6);Garrison, A.(6);Regueiro, M.(7);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)Kyorin University School of Medicine, Gastroenterology, Mitaka, Japan;(3)Karolinska University Hospital, Department of Gastroenterology- Dermatology- and Rheumatology, Stockholm, Sweden;(4)Fiona Stanley Hospital, Gestroenterology, Perth, Australia;(5)Ribeirão Preto Medical School- University of São Paulo, Department of Gastroenterology, Sao Paulo, Brazil;(6)AbbVie, none, North Chicago, United States;(7)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Dignass, A.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Rubin, D.T.(5);Regueiro, M.(6);
(1)University of Leuven, Chronic Diseases and Metabolism, Leuven, United States;(2)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(3)Icahn School of Medicine of Mount Sinai, Gastroenterology, New York, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(6)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;
